REPL Share Price | Replimune Group, Inc. Stock Analysis & Recommendation

Q: What does Replimune Group, Inc. do?

Overview: Replimune Group, Inc. is a clinical-stage biotechnology company engaged in oncolytic immunotherapy to treat cancer patients, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -74 Million (Quarterly Results - Mar 2025) Market cap: USD 732.71 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.04 Return on Equity: -59.47% Price to Book: 1.76Contact Details: Address: 500 Unicorn Park Dr, WOBURN MA: 01801-3377 Tel: ['1 781 2229600', '1 339 9702843'] Fax: 1 302 6555049 Website: https://www.replimune.com/

Q: Is Replimune Group, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Replimune Group, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The Bollinger Bands and KST also confirm a bearish outlook on both weekly and monthly time frames. Daily moving averages are bearish, further supporting this bearish sentiment. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. In terms of performance, Replimune has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -71.43% compared to the S&P 500's 12.22%, and a one-year return of -68.77% versus the S&P 500's 17.14%. Overall, the technical indicators strongly suggest a bearish outlook for the stock.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

574.47 k

Shareholding (Dec 2025)

FII

18.02%

Held by 95 FIIs

DII

38.64%

Held by 41 DIIs

Promoter

12.71%

How big is Replimune Group, Inc.?

22-Jun-2025

As of Jun 18, Replimune Group, Inc. has a market capitalization of 732.71 million and reported net sales of 0.00 million with a net profit of -247.29 million over the latest four quarters. Shareholder's funds are 415.84 million, and total assets amount to 551.33 million.

View full answer

What does Replimune Group, Inc. do?

22-Jun-2025

Replimune Group, Inc. is a clinical-stage biotechnology company focused on oncolytic immunotherapy for cancer treatment, with a market cap of approximately $732.71 million and a recent net profit loss of $74 million. The company has no dividend yield and negative return on equity.

View full answer

Who are in the management team of Replimune Group, Inc.?

22-Jun-2025

As of March 2022, the management team of Replimune Group, Inc. includes Mr. Dieter Weinand (Independent Chairman), Dr. Robert Coffin (President and Chief R&D Officer), and Mr. Philip Astley-Sparke (CEO). The Board also features independent directors such as Dr. Kapil Dhingra and Dr. Hyam Levitsky.

View full answer

Is Replimune Group, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Replimune Group, Inc. exhibits a bearish trend supported by negative MACD signals, bearish moving averages, and significant underperformance compared to the S&P 500, with year-to-date returns of -71.43% versus the S&P 500's 12.22%.

View full answer

Compare Replimune Group, Inc. with Similar Stocks

Syndax Pharmaceuticals, Inc.Protagonist Therapeutics, Inc.Pliant Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 608 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.03

Return on Equity

-149.55%

Price to Book

2.89

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-71 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.07%

6 Months

81.73%

1 Year

-31.58%

2 Years

-7.8%

3 Years

-61.78%

4 Years

-53.36%

5 Years

-74.98%

Replimune Group, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-216.38%

EBIT to Interest (avg)

-34.05

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.04

Sales to Capital Employed (avg)

Tax Ratio

0.52%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.89

EV to EBIT

-1.19

EV to EBITDA

-1.21

EV to Capital Employed

-56.61

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-149.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 47 Schemes (30.62%)

Foreign Institutions

Held by 95 Foreign Institutions (18.02%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -6.94% vs -29.75% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-70.60",
          "val2": "-65.40",
          "chgp": "-7.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-70.90",
          "val2": "-66.30",
          "chgp": "-6.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -14.60% vs -23.81% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-259.90",
          "val2": "-234.00",
          "chgp": "-11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.90",
          "val2": "6.70",
          "chgp": "17.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-247.30",
          "val2": "-215.80",
          "chgp": "-14.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-70.60

-65.40

-7.95%

Interest

2.00

Exceptional Items

0.00

Consolidate Net Profit

-70.90

-66.30

-6.94%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -6.94% vs -29.75% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-259.90

-234.00

-11.07%

Interest

7.90

6.70

17.91%

Exceptional Items

0.00

Consolidate Net Profit

-247.30

-215.80

-14.60%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -14.60% vs -23.81% in Mar 2024

All Annual Results

Company CV

About Replimune Group, Inc.

Replimune Group, Inc.

Pharmaceuticals & Biotechnology

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.

Company Coordinates

Company Details

500 Unicorn Park Dr , WOBURN MA : 01801-3377

Tel: 1 781 22296001 339 9702843

https://www.replimune.com/

Registrar Details